Please sign in to follow a disease.
Muscular dystrophy
MONDO:0020121Muscular dystrophy (MD) refers to a group of more than 30 genetic diseases characterized by progressive weakness and degeneration of the skeletal muscles that control movement. Some forms of MD are seen in newborns, infants or children, while others have late-onset and may not appear until middle age or later. The disorders differ in terms of the distribution and extent of muscle weakness (some forms of MD also affect cardiac muscle), age of onset, rate of progression, and pattern of inheritance. The prognosis for people with MD varies according to the type and progression of the disorder. There is no specific treatment to stop or reverse any form of MD. Treatment is supportive and may include physical therapy, respiratory therapy, speech therapy, orthopedic appliances used for support, corrective orthopedic surgery, and medicationsincluding corticosteroids, anticonvulsants (seizure medications), immunosuppressants, and antibiotics. Some individuals may need assisted ventilation to treat respiratory muscle weaknessor a pacemaker for cardiac (heart)abnormalities.
289 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New hope for FSHD: experimental drug AOC 1020 completes early testing
Disease control CompletedThis study tested a new medicine called AOC 1020 in 90 adults with facioscapulohumeral muscular dystrophy (FSHD), a genetic condition that causes muscle weakness. The goal was to check if the drug is safe and how the body processes it. Participants received either the drug or a p…
Phase: PHASE1, PHASE2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug aims to save hearts in duchenne muscular dystrophy
Disease control CompletedThis study tested an oral drug called ifetroban in 46 males aged 7 and older with Duchenne muscular dystrophy (DMD). The goal was to see if the drug is safe and can help prevent or treat heart problems, which are a leading cause of death in DMD. Participants received either ifetr…
Phase: PHASE2 • Sponsor: Cumberland Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Could a lower steroid dose plus exercise help boys with duchenne?
Disease control CompletedThis study looked at whether giving a steroid called prednisone twice a week at a lower dose, along with exercise training, could help boys with Duchenne muscular dystrophy (DMD) maintain muscle strength and function. The goal was to find a treatment that works as well as daily s…
Phase: PHASE2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug AOC 1001 tested for rare muscle disease
Disease control CompletedThis study tested a new drug called AOC 1001 in 39 adults with myotonic dystrophy type 1, a genetic muscle disorder. Participants received either the drug or a placebo by IV infusion. The goal was to check safety and how the drug moves through the body. Results will help decide i…
Phase: PHASE1, PHASE2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Experimental drug ataluren tested for safety in duchenne MD patients
Disease control CompletedThis study tested the safety of a drug called ataluren (also known as Translarna) in 270 people with Duchenne muscular dystrophy caused by a specific type of genetic mistake (nonsense mutation). Participants had already taken ataluren in earlier studies. The goal was to monitor s…
Phase: PHASE3 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug aims to help boys with duchenne walk longer
Disease control CompletedThis study tested a drug called ataluren in 360 boys with Duchenne muscular dystrophy caused by a specific genetic mistake (nonsense mutation). The main goal was to see if ataluren could help them walk farther over 72 weeks compared to a placebo. All participants were also taking…
Phase: PHASE3 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
CRISPR therapy shows promise in early trial for fatal muscle disease
Disease control CompletedThis early-phase study tested a new gene editing treatment called HG302 in 4 boys with Duchenne muscular dystrophy (DMD), a severe muscle-wasting disease. The therapy uses CRISPR technology to fix the genetic error and help muscles produce dystrophin, a protein essential for musc…
Phase: EARLY_PHASE1 • Sponsor: HuidaGene Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug PGN-EDODM1 tested for muscle disease
Disease control CompletedThis early-stage trial tested a single dose of the drug PGN-EDODM1 in 24 adults with myotonic dystrophy type 1, a genetic muscle disorder. The main goal was to check safety and how the body handles the drug. The study is complete, but results are not yet available.
Phase: PHASE1 • Sponsor: PepGen Inc • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Tailored diet shows promise for young duchenne patients
Disease control CompletedThis study tested whether a personalized diet could improve nutrition and movement in children aged 4-8 with Duchenne muscular dystrophy (DMD). Nine children in Ankara, Turkey, received dietary counseling focused on energy, protein, calcium, and fluid needs. Researchers measured …
Phase: NA • Sponsor: Ankara University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New drugs aim to keep boys with duchenne walking longer
Disease control CompletedThis study tested two drugs, casimersen and golodirsen, in 228 boys with Duchenne muscular dystrophy who have specific genetic mutations. The goal was to see if these drugs could slow muscle decline, measured by how fast they could climb four steps. Participants received either t…
Phase: PHASE3 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New steroid hope for duchenne boys: safer muscle treatment?
Disease control CompletedThis study tested a drug called vamorolone in 54 boys with Duchenne muscular dystrophy, aged 2 to under 4 years and 7 to under 18 years. The goal was to check safety and how the body processes the drug over 12 weeks. Researchers hope vamorolone may help control the disease with f…
Phase: PHASE2 • Sponsor: Santhera Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug shows promise for rare muscle disease in kids
Disease control CompletedThis study tested a drug called tideglusib against a placebo in 56 children aged 6 to 16 with congenital myotonic dystrophy, a rare genetic muscle disorder. The goal was to see if tideglusib could reduce symptoms like muscle weakness and breathing problems. The trial was complete…
Phase: PHASE2, PHASE3 • Sponsor: AMO Pharma Limited • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Experimental drug AOC 1001 tested for Long-Term safety in rare muscle disease
Disease control CompletedThis study is a follow-up to an earlier trial, testing the long-term safety and effects of a drug called AOC 1001 in adults with myotonic dystrophy type 1 (DM1), a genetic muscle disease. 37 participants who completed the first study received multiple doses of AOC 1001 by IV infu…
Phase: PHASE2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New Steroid-Like drug tested for muscle disease
Disease control CompletedThis phase 2 trial tested vamorolone, a drug similar to steroids, against a placebo in 46 males with Becker muscular dystrophy. The goal was to check safety and tolerability over 24 weeks, while also looking for early signs of benefit. The study is complete, but results are not y…
Phase: PHASE2 • Sponsor: ReveraGen BioPharma, Inc. • Aim: Disease control
Last updated Jun 26, 2026 18:34 UTC
-
Experimental drug tideglusib tested for rare muscle disease
Disease control CompletedThis phase 2 study tested the safety and effectiveness of tideglusib, an experimental drug, in 16 adolescents and adults with congenital or juvenile-onset myotonic dystrophy type 1. Participants received either 400 mg or 1000 mg of tideglusib daily. The study measured side effect…
Phase: PHASE2 • Sponsor: AMO Pharma Limited • Aim: Disease control
Last updated Jun 26, 2026 16:48 UTC
-
Experimental gene therapy targets rare form of duchenne muscular dystrophy
Disease control CompletedThis early-stage trial tested a single-dose gene therapy called scAAV9.U7.ACCA in 3 boys with Duchenne muscular dystrophy caused by a duplication of exon 2. The therapy was given through a vein and aimed to help muscle cells produce dystrophin, a protein missing in this disease. …
Phase: PHASE1, PHASE2 • Sponsor: Megan Waldrop • Aim: Disease control
Last updated Jun 26, 2026 16:38 UTC
-
AI spots rare muscle disease from a simple video
Diagnosis CompletedThis completed pilot study tested whether a computer algorithm could diagnose facioscapulohumeral muscular dystrophy (FSHMD) by analyzing video recordings of people's faces. Researchers recorded 17 participants, including patients with FSHMD, other muscle diseases, and healthy co…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Diagnosis
Last updated Jun 27, 2026 12:37 UTC
-
New scale could help predict fall risk for hospital patients in turkey
Diagnosis CompletedThis study tested a Turkish version of the Johns Hopkins In-Room Independence Scale, which measures a patient's ability to move, use the toilet, and think clearly while in their hospital room. Researchers worked with 100 adults who had conditions like stroke, Parkinson's, or ampu…
Sponsor: Sisli Hamidiye Etfal Training and Research Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 09:08 UTC
-
New blood test could replace risky prenatal procedures for genetic diseases
Diagnosis CompletedThis study aimed to develop a non-invasive prenatal test using fetal cells from a mother's blood to detect triplet repeat diseases like Huntington's disease, Fragile X syndrome, and certain types of muscular dystrophy and ataxia. Researchers enrolled 60 pregnant women at risk and…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Diagnosis
Last updated Jun 27, 2026 07:53 UTC
-
Heart drug fails to shield duchenne boys from cardiac decline
Prevention CompletedThis study tested whether nebivolol, a beta-blocker heart drug, could prevent heart failure in 51 boys aged 10-15 with Duchenne muscular dystrophy. Participants had normal heart function at the start and were randomly given either nebivolol or a placebo. The trial found that nebi…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Prevention
Last updated Jun 27, 2026 07:58 UTC
-
Robotic arm could help people with paralysis regain independence at home
Symptom relief CompletedThis study tests whether a wheelchair-mounted robotic arm called Jaco helps people with tetraplegia perform daily tasks like grasping and reaching at home. Participants use the device for two months after training. Researchers measure changes in performance and satisfaction with …
Phase: NA • Sponsor: Association APPROCHE • Aim: Symptom relief
Last updated Jul 04, 2026 00:00 UTC
-
New adjustable brace shows promise for kids with crouch gait
Symptom relief CompletedThis study tested a new type of leg brace designed to help children with cerebral palsy and other movement disorders walk more easily. The brace was custom-made for each child and could be adjusted to provide different kinds of support. Researchers measured how well children walk…
Phase: NA • Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Could virtual reality help kids with a rare muscle disease read emotions better?
Symptom relief CompletedThis study tests whether virtual reality training can help children aged 6 to 16 with the childhood form of myotonic dystrophy type 1 (DM1) improve their ability to understand others' thoughts and emotions. Participants engage in social scenarios in a virtual environment, guided …
Phase: NA • Sponsor: Institut de Myologie, France • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
New study tracks Long-Term safety of muscle stiffness drug namuscla
Symptom relief CompletedThis study followed 53 adults with non-dystrophic myotonic disorders who were taking Namuscla (mexiletine) to manage muscle stiffness. Researchers monitored side effects and how often patients needed to reduce their dose or stop treatment over up to 36 months. The goal was to see…
Sponsor: Lupin Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Video games as therapy: VR shows promise for children with muscle disorders
Symptom relief CompletedThis study tested whether virtual reality (using Xbox Kinect) or biofeedback training could improve motor function and balance in 24 children with neuromuscular diseases like Duchenne muscular dystrophy and spinal muscular atrophy. Participants were split into three groups: VR tr…
Phase: NA • Sponsor: Merve Kurt • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
VR game helps kids with muscle disease do their exercises
Symptom relief CompletedThis study tested whether an interactive virtual reality (VR) system could help children aged 5–10 with Duchenne muscular dystrophy (DMD) stick to their physiotherapy exercises at home. Fourteen children used the VR system for 8 weeks, and researchers measured how often and how l…
Phase: NA • Sponsor: Sheffield Children's NHS Foundation Trust • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC
-
Robotic leg device shows promise for helping muscle disease patients walk
Symptom relief CompletedThis study tested a powered leg exoskeleton (Keeogo) in 50 people with various muscle disorders to see if it is safe and helps them walk better. Participants performed walking tests with and without the device. The goal was to see if the device could improve walking distance and …
Phase: NA • Sponsor: Institut de Myologie, France • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Robotic exoskeleton shows promise for muscle disease patients
Symptom relief CompletedThis study tested a wearable robotic suit called MyoSuit that assists knee and hip movement in people with various muscle disorders. 32 participants used the device to perform walking tests, and researchers checked for safety and any immediate improvements in walking ability. The…
Phase: NA • Sponsor: Institut de Myologie, France • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Physiotherapy students test muscle relief techniques on themselves
Symptom relief CompletedThis study looked at how common muscle and posture problems are in physiotherapy students and whether a special physiotherapy program could help. 44 students with back pain and muscle tightness received treatments like trigger point release, stretching, and joint mobilization. Th…
Phase: NA • Sponsor: Charles University, Czech Republic • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Video games and shake therapy: a new way to build muscle in DMD kids?
Symptom relief CompletedThis study looked at whether virtual reality exercises and whole-body vibration can improve muscle strength and balance in children with Duchenne muscular dystrophy (DMD). Fifty children aged 6 to 10 years who could still walk took part. The goal was to see if these fun, non-drug…
Phase: NA • Sponsor: Cairo University • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
Who should control your sedation during surgery? new study compares options
Symptom relief CompletedThis study looked at whether letting patients control their own sedation during arm surgery under regional anesthesia leads to higher satisfaction compared to having an anesthesiologist control it. 70 adults having upper limb orthopedic surgery were randomly assigned to either pa…
Phase: NA • Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche • Aim: Symptom relief
Last updated Jun 27, 2026 07:59 UTC
-
Breathing training from home shows promise for DMD children
Symptom relief CompletedThis study tested whether breathing muscle exercises done at home via video calls could improve lung function and quality of life in 40 children with Duchenne muscular dystrophy. The children, aged 5-17, used a device to strengthen their breathing muscles. Researchers measured ch…
Phase: NA • Sponsor: Izmir Katip Celebi University • Aim: Symptom relief
Last updated Jun 26, 2026 17:16 UTC
-
New turkish health survey could improve care for muscle and joint problems
Knowledge-focused CompletedThis study translated the Generic Functional Index, a questionnaire that measures how well people can do daily activities, into Turkish. Researchers tested it with 200 adults who have muscle or joint problems to see if it is accurate and reliable. The goal is to give Turkish-spea…
Sponsor: Istanbul Bilgi University • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Study reveals financial toll of duchenne MD on french families
Knowledge-focused CompletedThis study looked at the extra costs that families of people with Duchenne muscular dystrophy (DMD) in France have to pay out of their own pockets. It included 28 patients of any age who had been diagnosed for at least six months. The researchers measured things like uninsured me…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Home Check-Ups for DMD: a new study tests if Tele-Assessments are reliable
Knowledge-focused CompletedThis study tested whether doctors can accurately assess physical function and quality of life in children with Duchenne muscular dystrophy (DMD) through video calls. Twenty ambulatory patients aged 5-18 completed timed tests and questionnaires remotely. The goal was to see if tel…
Sponsor: Sahra Şirvan • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Tiny study probes muscle oxygen in rare nerve and muscle diseases
Knowledge-focused CompletedThis completed study looked at how muscle oxygen levels change during exercise in people with various neuromuscular diseases compared to healthy volunteers. Seventeen participants did a knee-extension exercise while a device measured muscle oxygen. The goal was to understand diff…
Phase: NA • Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Inflammation may be key in rare muscle disease
Knowledge-focused CompletedThis pilot study examined whether inflammation, measured by cytokines in the blood, plays a role in type 1 facioscapulohumeral muscular dystrophy (FSHD1). Researchers compared 20 FSHD1 patients with healthy controls to see if certain inflammatory markers are higher in the disease…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Heart risk study for muscular dystrophy patients completed
Knowledge-focused CompletedThis study looked at 537 people with myotonic dystrophy type 1 to understand their risk of serious heart rhythm problems, including sudden cardiac arrest. Researchers tracked participants for two years to see how often these events happened and what factors might predict them. Th…
Phase: NA • Sponsor: Catholic University of the Sacred Heart • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Physios take on ER duty: study tests if they can replace doctors for back pain
Knowledge-focused CompletedThis study tested whether specially trained physiotherapists can safely diagnose and treat non-urgent muscle and joint pain in the emergency room, compared to standard care from doctors. 102 patients with back, neck, or shoulder pain were randomly assigned to either a physiothera…
Phase: NA • Sponsor: Bern University of Applied Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Home videos could help track duchenne muscular dystrophy
Knowledge-focused CompletedThis completed study enrolled 150 people with Duchenne muscular dystrophy to create a video database of their movement abilities. Caregivers recorded children doing specific tasks at home using a secure app. The goal was to help validate a new tool called the Duchenne Video Asses…
Sponsor: The Emmes Company, LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
New tool could better track facial muscle health in rare muscle disease
Knowledge-focused CompletedThis study tested a new method to evaluate the strength and function of face and mouth muscles in people with facioscapulohumeral muscular dystrophy (FSHD). Twenty-two adults with a genetic diagnosis of FSHD took part. The goal was to see if this new assessment tool can reliably …
Phase: NA • Sponsor: University of Mons • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
New study maps key tests for LGMD to speed up drug development
Knowledge-focused CompletedThis study involved 116 people with Limb Girdle Muscular Dystrophy (LGMD), a group of rare muscle-weakening disorders. Researchers measured how well participants could walk, move their arms, and breathe, and asked about their daily activities and overall health. The goal was to i…
Sponsor: Virginia Commonwealth University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Calf muscle shape linked to walking ability in DMD kids
Knowledge-focused CompletedThis study measured calf muscle thickness and length in 26 children with Duchenne muscular dystrophy (ages 6-12) who could still walk. Researchers used ultrasound and motion analysis to see how muscle structure relates to walking and other movements. The goal was to better unders…
Sponsor: Deraya University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
Real-World data on duchenne drug translarna collected in large safety study
Knowledge-focused CompletedThis study followed 316 people with Duchenne muscular dystrophy who were taking Translarna (ataluren) as part of their normal medical care. The goal was to monitor side effects and see how well the drug works in everyday use. Researchers also checked if doctors and patients follo…
Sponsor: PTC Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
New app could help track muscle disease from your living room
Knowledge-focused CompletedThis study tested whether a mobile app (myFSHD) can help doctors monitor patients with facioscapulohumeral muscular dystrophy (FSHD) remotely. 70 adults with FSHD used the app at home for 12 months, completing questionnaires and video-recorded exercises. The goal was to see if pa…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
New study tracks muscle decline in rare disease to guide future treatments
Knowledge-focused CompletedThis study followed 52 people with limb-girdle muscular dystrophy 2I (LGMD2I) for up to two years to learn more about how the disease changes over time. Researchers measured walking ability, muscle strength, heart function, and daily activities. The goal was to better understand …
Sponsor: Genethon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Healthy men test drug for muscular dystrophy
Knowledge-focused CompletedThis early-stage trial tested a single dose of the study drug GRT6019 in 18 healthy men to check its safety and how the body processes it. The study also looked at whether food changes drug absorption. Results will guide future research for Duchenne muscular dystrophy, but this t…
Phase: PHASE1 • Sponsor: Grünenthal GmbH • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
New study aims to sharpen tools for measuring muscle decline in common adult muscular dystrophy
Knowledge-focused CompletedThis study followed 30 adults with myotonic dystrophy type 1 (Steinert disease) and 30 healthy volunteers over three years to see how muscle strength and function change naturally over time. Researchers measured things like muscle power, walking ability, and nerve responses to fi…
Sponsor: Institut de Myologie, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Sound waves could spot early signs of rare muscle disease
Knowledge-focused CompletedThis study tested whether ultrasound can detect early facial muscle changes in people with facioscapulohumeral muscular dystrophy (FSHD), a rare muscle disease. Researchers compared 20 FSHD patients with 19 healthy adults, measuring muscle thickness and echo intensity in key faci…
Sponsor: Koç University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
New study aims to uncover why some myotonic dystrophy patients develop low breathing
Knowledge-focused CompletedThis study followed 113 adults with myotonic dystrophy (Steinert's disease) for 5 years to find out what factors lead to low breathing (hypoventilation). Researchers measured lung function, sleepiness, fatigue, and thinking skills. The goal is to better understand which patients …
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC
-
Can CRPS patients imagine movement? new study investigates
Knowledge-focused CompletedThis completed study compared how well people with complex regional pain syndrome (CRPS), people with other muscle or bone pain, and healthy individuals can imagine movements. Researchers used a questionnaire called the MIQ-RS to measure motor imagery skills. The goal was to see …
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Mind, spirit, and pain: new study explores what chronic pain patients really believe
Knowledge-focused CompletedThis study surveyed 116 adults with chronic pain at a rehabilitation clinic to understand how their pain beliefs, spiritual well-being, and attitudes toward complementary and alternative medicine are related. Participants filled out several questionnaires about their pain, mood, …
Sponsor: Gulseren Demir Karakilic • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
Hidden danger: muscle disease linked to deadly clots
Knowledge-focused CompletedThis study investigates why people with myotonic dystrophy type 1 are 10 times more likely to develop dangerous blood clots in the legs or lungs. Researchers will compare blood samples from 130 participants—including patients with the disease, those with a history of clots, and h…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:53 UTC